Genedata AG Screener Strengthens Collaborative Research At Axxam

Published: Sep 28, 2017

Platform enables consistent production of high-quality data and increases the pace of innovation at CROs and PROs

Basel, Switzerland - September 27, 2017 - Genedata, a leading provider of advanced software solutions for R&D, today announced that Axxam has extended its licensing of Genedata Screener® as its collaborative research platform for data analysis of high-throughput screening, compound profiling, and safety screening campaigns. As an innovative Partner Research Organization (i-PRO), Axxam provides integrated discovery services for the whole life sciences industry. The Genedata Screener platform is used to streamline and standardize Axxam screening workflows, and Axxam has successfully extended its use of Genedata Screener as a collaboration platform with its many biopharma clients and partners.

Genedata Screener: Competitive Edge for CROs and PROs Contract Research Organizations (CROs) and PROs such as Axxam benefit from the increased outsourcing of discovery services by biopharmaceutical companies. To remain competitive, these organizations always look for ways to quicken the pace of service delivery and provide value-added service offerings. Genedata Screener, used by the majority of the world’s top biopharmas, delivers on both fronts and enables PROs to:

Reduce data analysis processing times by orders of magnitude compared to other software packages Standardize experimental workflows to improve consistency and reduce overhead and costs Streamline collaboration and data exchange processes with pharma clients Support compliance with their pharma clients’ stringent QC requirements Deliver high-value offerings based on best-practice data analysis Introduce innovative screening technologies to their service portfolio

“Since 2008, we have been using Genedata Screener for high throughput screening programs,” says Dr. Stefan Lohmer, CEO of Axxam. “The platform is integral to all our screening service offerings and provides everything our customers are looking for in terms of data comparability, traceability, and quality of results.”

Web-based and cloud-ready, Genedata Screener gives Axxam a collaborative platform that simplifies data- and result-sharing. It supports different collaboration models between i-PROs and pharmaceutical companies, such as multi-tiered and peer-to-peer, which empowers new approaches to drug discovery.

“The cost savings, productivity gains, and increased opportunities for innovative R&D are driving the increased adoption of Genedata Screener by the world’s leading PROs,” noted Dr. Othmar Pfannes. “We are committed to supporting PROs and their clients in their collaborations to make biopharmaceutical R&D processes more efficient.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.

www.genedata.com Follow Us on LinkedIn

Media Contacts
Helena Bonin
Genedata Screener Marketing Manager
helena.bonin@genedata.com

Jackie Thrasivoulos
Genedata Screener Public Relations
jackie.thrasivoulos@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events, or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Back to news